Highest-materiality recent filing
MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC
First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.
MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC
Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.
MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L
Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.
MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC
Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.
MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/sh
Closed underwritten public offering of 20M shares at $1.50/sh, gross proceeds $30M.
MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status
Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.
MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC
Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.
MAIA Biotechnology announces $1.51M private placement of common stock and warrants
Gross proceeds ~$1.51M from 1,233,488 shares at $1.224 each, with warrants exercisable at $1.36.
MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC
First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.
MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting
FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.
12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.
MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented
One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.
MAIA Biotechnology to hold up to 90% of liquid assets in Bitcoin, Ethereum, and USDC
Board authorized up to 90% of liquid assets to be held in cryptocurrencies: BTC, ETH, and USDC.
MAIA Biotechnology announces $2.25M private placement of stock and warrants
Gross proceeds ~$2.25M from sale of 1,733,766 shares at $1.30; one warrant per share at $1.57 exercise price.
MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC
NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.
MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC
Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.
European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.
MAIA Biotech gets FDA Fast Track for ateganosine in NSCLC; Phase 2 data shows 17.8-month median OS
FDA granted Fast Track designation for ateganosine (THIO) for treatment of non-small cell lung cancer.
First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.
Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.
MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies
Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.
MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months
Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.
MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025
Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.
MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO
Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.
MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025
Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.
MAIA plans Phase 3 pivotal trial of THIO+CPI vs chemo in NSCLC patients
Phase 3 trial THIO-104 to enroll up to 300 patients with third-line NSCLC.
On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.
On November 10, 2023, Joseph McGuire and Dr. Mihail Obrocea were terminated from their positions as Chief Financial Officer (and principal financial and accounting officer) and Chief Medical Officer, respectively, of the Company, effective immediately, as part of the Company’s effort to streamline operations.
On the same date, the Company appointed Jeffrey Himmelreich as its Head of Finance and principal financial and accounting officer.
On March 17, 2023, upon the recommendation of the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board, the Board elected Jean-Manassé Theagène to serve as a Class III director of the Board, with immediate effect, until the Company’s 2025 annual meeting of stockholders, or until such time as he resigns or is removed, and his successor has been elected and qualified.
On March 13, 2023, Laurentiu Vlad notified MAIA Biotechnology, Inc. (the “Company”) that he is resigning from the Board of Directors (the “Board”) of the Company effective on March 16, 2023, due to personal reasons.
Max materiality 0.85 · Median 0.60 · Most common event other_material